Govind Warrier

Assistant Professor of Oncology

Johns Hopkins University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Background The administration of incentives to promote physical activity, such as the amount or timing, can vary depending on target health behaviors, research settings, intervention delivery channels, and participants’ preferences. Interventions implemented at scale necessitate the consideration of potential fiscal constraints for public health promotion. Since limited funding is a barrier to implementing community-based interventions, examining both immediate and sustained effects of temporary incentive increases on physical activity is important. Objective This study aimed to evaluate the effect of a 1-week double-point event on increasing physical activity among low-engaged individuals in the context of a community-based mobile intervention. Methods Using retrospective data from a Seoul Metropolitan Government mobile health (mHealth) intervention, we evaluated the effects of a 1-week double-point incentive on participants’ physical activity. During 3 registration phases from November to December 2021, a total of 50,145 individuals enrolled. Our analysis focused on the low-engaged group (n=27,833, 55.5%), who averaged fewer than 3 days per week of meeting the daily step challenge (at least 7000 steps) before the intervention. We performed a segmented regression analysis to assess changes in physical activity before and after the event. Multivariable logistic regression and Cox proportional hazards models were used to identify factors associated with improving and maintaining physical activity after starting the intervention. Results Of 27,833 low-engaged participants, only 13.7% (n=3835) improved their physical activity. Daily challenge engagements per week increased by 2.53 times, and average daily steps increased by 1924.97 (standardized mean difference 0.55, 95% CI 0.51‐0.58). In multivariable logistic regression, older age was significantly associated with improved physical activity immediately after starting the intervention. However, 50% (1918/3835) of the improved group was likely to return to low engagement 3 weeks after the intervention ended. Older age and use of certain wearable devices were associated with maintaining physical activity after the intervention. Conclusions Double-point incentives in the short term may serve as a cue-to-action to motivate low-engagement targets; however, they do not seem to guarantee long-term maintenance in the context of community-based mHealth interventions. Further research is needed to identify additional strategies beyond monetary incentives to sustain long-term healthy behavior.

Year:

2025

Background Mobile health (mHealth) holds promise for enhancing patient care, yet attrition in its use remains a major barrier. Low retention rates limit its potential impact, while barriers to accessing or adopting mHealth vary across populations and countries. These differences in utilization of mHealth may exacerbate health inequalities, contributing to the digital health divide. Objective We aimed to conduct a systematic review and meta-analysis to investigate the factors associated with inequalities in mHealth utilization across different implementation phases, including access, adoption, adherence, and maintenance. Methods This systematic review and meta-analysis analyzed mHealth research from 2000 to May 30, 2024, using databases, including PubMed, Web of Science, MEDLINE, and ProQuest. Eligible studies included smartphones, mHealth apps, wearables, and inequality indicators across 4 mHealth phases: access, adoption, adherence, and maintenance. Excluded studies were nonpeer-reviewed, opinion-based, or not in English. Extracted data included study characteristics, target populations, health outcomes, and inequality factors like age, gender, socioeconomic status, and digital literacy. Factors were categorized using a digital health equity framework (biological, behavioral, sociocultural, digital, health care system, and physical domains). Meta-analyses were performed using a random-effects model for factors reported in at least three studies, with heterogeneity assessed by the I ² statistic. Results Among 1990 studies, 62 studies met the inclusion criteria, and 30 studies underwent meta-analysis. The phases of mHealth utilization were access (n=23, 37%), adoption (n=47, 76%), adherence (n=9, 15%), and maintenance (n=2, 3%). Meta-analysis showed older age was negatively associated with mHealth adoption (odds ratio [OR] 0.47, 95% CI 0.23‐0.93), while higher education and income were positively associated in both access and adoption phases. Employment showed significant associations in the access phase (OR 1.49, 95% CI 1.08‐2.05), whereas comorbidities (OR 1.39, 95% CI 1.03‐1.86) and private insurance (OR 1.63, 95% CI 1.07‐2.48) were significantly associated with adoption of mHealth. Women (OR 1.24, 95% CI 1.06‐1.45) and physically active individuals (OR 1.64, 95% CI 1.07‐2.50) were more likely to adopt mHealth. Conclusions The conceptual framework outlined in this study highlights the multifaceted nature of mHealth utilization across all the phases of mHealth engagement. To address these inequalities, tailored and personalized interventions are required at each phase of mHealth utilization. Targeted efforts can enhance digital access for older and low-income adults while promoting engagement through education, insurance support, and healthy behaviors, thereby promoting equitable and effective mHealth use. By recognizing the interconnectedness of these domains, policy makers and health care stakeholders can design interventions that not only address the phase-specific barriers but also bridge broader inequalities in health care access and engagement.

Year:

2025

Background The biological sciences are producing increasingly larger datasets for biomarker discovery. While common data models have been developed for medical terms as they relate to patient health outcomes, a data model that supports longitudinal tracking of biospecimens and relating them against an individual patient experience is a large, unmet need. Method A structure and associated taxonomy were achieved through a six-tier build in Research Electronic Data CAPture (REDCap), which organizes the complexity of the therapeutic decisions, biospecimens, and outcomes that characterize a longitudinal patient experience. Modules were developed to support export of REDCap data into a Structured Query Language (SQL) format for merging with extended biomarker data, also housed in SQL. Results The resultant AstroID resource is a relational structure for clinical and biospecimen data that meets several desired goals: searchable, flexible, generic, Health Insurance Portability and Accountability Act-compliant, auditable, and easy-to-use. The essential elements forming the core of the six-tiered build are provided, so others can readily adopt this schema, as well as an example of an extended, customized build to support biomarker discovery for patients with melanoma. Two examples where this data structure was used to support biomarker discovery and development are described, and example queries of the database are also presented. To the extent possible, the data dictionary was aligned with large data models, such as those for the National Institutes of Health’s Human Tumor Atlas Network. The structure can readily scale to accommodate thousands of patients, multimodality data, and spatial characterization of billions of cells. Radiologic imagery can also be included along with pathology imagery to support spatial studies, including artificial intelligence-driven analyses. Conclusions This effort provides a database model for investigators conducting research on large volumes of biospecimens with clinical annotation. We have now deployed this structure in our laboratories and have over 1B cells spatially mapped, each effectively tagged with the clinical information from longitudinal patient experiences. While the description uses the example of cancer biomarkers, this data structure could be used to characterize longitudinal biospecimens from any disease process. In the near future, automatic synchronization between the electronic medical record and one or more AstroID databases is anticipated.

Year:

2025

Background Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment, with programmed cell death protein 1 (PD-1) inhibitors—alone or in combination with cytotoxic T-lymphocyte–associated protein 4 or lymphocyte-activation gene 3 inhibitors—demonstrating significant efficacy. However, there is a critical lack of robust data to determine the optimal sequencing of these therapies for individual patients. In particular, the role of relatlimab+nivolumab (rela/nivo) within treatment sequences remains poorly defined. Choosing the right sequence is strategic, as an inappropriate order may compromise the effectiveness of subsequent treatments and limit long-term benefits. Methods This multicenter retrospective and prospective study evaluated 190 patients across three treatment arms: rela/nivo followed by ipilimumab+nivolumab (ipi/nivo) (arm A, N=40), ipi/nivo followed by rela/nivo (arm B, N=71), and anti-PD-1 followed by rela/nivo (arm C, N=79). The study assessed the impact of treatment sequencing on outcomes including response rate, progression-free survival, and overall survival (OS). Results The overall response rate to second treatment was highest in arm C (30.4%), followed by arm B (28.1%) and arm A (17.5%). Patients with secondary resistance to first-treatment ICIs had better responses to second-treatment ICIs than those with primary resistance, particularly in arm B (p=0026). Median OS from date of first ICI treatment was significantly longer in arms B (40.9 months) and C (42.5 months) compared with arm A (16.3 months). Conclusions Our findings indicate that rela/nivo may remain active following anti-PD-1 or ipi/nivo therapy. Additionally, our results suggest that sequencing ipi/nivo before rela/nivo may yield better outcomes than starting with rela/nivo. Patients who respond to the first combination regimen appear to derive greater benefit from the second. Further efforts are needed to optimize sequencing strategies in advanced melanoma, and future studies should consider the impact of prior treatment outcomes.

Year:

2025

BACKGROUND Community-based mHealth interventions for physical activity are being implemented in many countries; however, maintaining user engagement remains challenging. Therefore, the impact of additional short-term monetary incentives on low-engaged (LE) participants needs to be elucidated as a potential alternative. OBJECTIVE This study aimed to evaluate the effectiveness of an additional financial incentive, specifically a double-point event, within a community-based mHealth intervention designed to increase physical activity among individuals with low engagement. METHODS Using retrospective data from a Seoul Metropolitan Government mHealth intervention, we evaluated the effects of a one-week double-point incentive on participants’ physical activity. During three registration phases from November to December 2021, 50,145 individuals enrolled. Our analysis focused on the LE group (n=27,833, 55.5%), who averaged fewer than three days per week of meeting the daily step challenge (at least 7,000 steps) before the intervention. We performed a segmented regression analysis to assess changes in physical activity before and after the event. Multivariable logistic regression and Cox proportional hazards models were employed to identify factors associated with improving and maintaining physical activity after starting the intervention. RESULTS Out of 27,833 LE participants, only 137% (n=3,835) improved their physical activity. Daily challenge engagements per week increased by 253 times, and average daily steps increased by 192497 (SMD=0.55, 95% CI: 0.51-0.58). In multivariable logistic regression, older age was significantly associated with improved physical activity immediately after starting the intervention. However, 50% of the improved group was likely to return to low engagement three weeks after the intervention ended. Older age and use of certain wearable devices were associated with the maintenance of physical activity after the intervention. CONCLUSIONS Double-point incentives in the short term may serve as a cue-to-action to motivate low-engagement targets; however, they do not seem to guarantee long-term maintenance in the context of community-based mHealth interventions. Further research is needed to identify additional strategies beyond monetary incentives to sustain long-term healthy behavior

Year:

2024

Year:

2023

Year:

2023

Collaborators (15)

caroline robert

- Directeur de l’équipe «Résistance thérapeutique» dans l’Unité INSERM U 981 : Biomarqueurs prédicteurs et nouvelles stratégies moléculaires en thérapeutique anticancéreuse

Université de Paris Faculté de Santé

FRANCE
View details

Robin van Kessel

London School of Economics and Political Science

UNITED KINGDOM
View details

Reinhard Dummer

University Hospital of Zurich

SWITZERLAND
View details

Jenny K. Hoang

Associate Professor of Radiology

Johns Hopkins University School of Medicine

UNITED STATES
View details

Alexander M. Menzies

University of Sydney

AUSTRALIA
View details

Joel Sunshine

Assistant Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Alexander S. Szalay

Johns Hopkins University

UNITED STATES
View details

Johannes Thrul

Associate Professor

Johns Hopkins University Bloomberg School of Public Health

UNITED STATES
View details

Michael A. Postow

Weill Cornell Medical College

UNITED STATES
View details

F. Dimitriou

Attending Physician, Head of Skin Cancer Center

University Hospital of Bern

SWITZERLAND
View details

Ryan Sullivan

Harvard University

UNITED STATES
View details

Paolo Antonio Ascierto

Full Professor

Università degli Studi di Napoli Federico II

ITALY
View details

Andrew R. Carey

Johns Hopkins Medicine Wilmer Eye Institute

UNITED STATES
View details

Juhee Cho

Professor

Sungkyunkwan University

SOUTH KOREA
View details

Ines Pires da Silva

Medical Oncologist

University of Sydney

AUSTRALIA
View details